Celltrion Healthcare Presents Clinical Data Showing That Inflammatory Bowel Disease Patients Should Be Treated With Biosimilar Monoclonal Antibody (mAb) Infliximab

Celltrion Healthcare Presents Clinical Data Showing That Inflammatory Bowel Disease Patients Should Be Treated With Biosimilar Monoclonal Antibody (mAb) Infliximab
Documented clinical experience was recently presented by Celltrion Healthcare's satellite symposium during the 2014 United European Gastroenterology (UEGW) showing evidence that patients with inflammatory bowel disease (IBD) -- Crohn’s disease and ulcerative colitis -- should be treated with the biosimilar monoclonal antibody (mAb) infliximab. Infliximab is an anti-TNF therapy suitable for patients with IBD12; it is considered a therapy for controlling disease symptoms over the long term. Biologic therapies for IBD are designed around particular proteins and enzymes that have been proven to be excessive, defective, or deficient in people with Crohn’s disease or ulcerative colitis. Biologic agents, unlike conventional treatment with corticosteroids and other therapies that tend to suppress the entire immune system, act very specifically with minor side effects. Jørgen Jahnsen, Professor of Gastroenterology at University of Oslo in Norway, and a leading expert in the field of IBD, reported that his clinical experience of treating people
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *